Abstract
This special issue of Frontiers in Neuroscience-Neurodegeneration celebrates the 50th anniversary of John Olney’s seminal work introducing the concept of excitotoxicity as a mechanism for neuronal cell death. Since that time, fundamental research on the pathophysiological activation of glutamate receptors has played a central role in our understanding of excitotoxic cellular signaling pathways, leading to the discovery of many potential therapeutic targets in the treatment of acute or chronic/progressive neurodegenerative disorders. Importantly, excitotoxic signaling processes have been found repeatedly to be closely intertwined with oxidative cellular cascades. With this in mind, this review looks back at long-standing collaborative efforts by the authors linking cellular redox status and glutamate neurotoxicity, focusing first on the discovery of the redox modulatory site of the N-methyl-D-aspartate (NMDA) receptor, followed by the study of the oxidative conversion of 3,4-dihydroxyphenylalanine (DOPA) to the non-NMDA receptor agonist and neurotoxin 2,4,5-trihydroxyphenylalanine (TOPA) quinone. Finally, we summarize our work linking oxidative injury to the liberation of zinc from intracellular metal binding proteins, leading to the uncovering of a signaling mechanism connecting excitotoxicity with zinc-activated cell death-signaling cascades.
Introduction
Reduction and oxidation reactions lie at the heart of critical biochemical processes indispensable for life. Indeed, there is no need to look much beyond oxidative phosphorylation to appreciate the essential nature of redox biology (Lehninger, 1945; Hill, 1951; Ernster and Lee, 1964). The aim of this review is to illustrate key redox processes as they relate to neuronal excitotoxicity that have been collaboratively explored by the authors over the last 30 years. In the first part of the review, we describe the experiments that led to the discovery of the redox modulatory site on the NMDA receptor (Aizenman et al., 1989). We then summarize the key observations that followed this finding, tightly linking the redox modulatory site to excitotoxic phenomena (Aizenman and Reynolds, 1992). In the second part of the review, we outline the studies we performed characterizing the oxidative conversion of the catecholamine precursor 3,4-dihydroxyphenylalanine (DOPA) to the kainate-like excitotoxin 2,4,5-trihydroxyphenylalanine (TOPA) quinone (Aizenman et al., 1990b; Rosenberg et al., 1991) culminating with the demonstration that TOPA quinone could be generated by catecholamine-containing cells, thereby introducing a novel mechanism of neurodegeneration in the study of endogenous neurotoxic processes in the brain (Newcomer et al., 1995b). We then transition to describe our work that first described the oxidative liberation of intracellular zinc in neurons (Aizenman et al., 2000). This process, which is closely associated with excitotoxic injury, results in a now-well characterized, complex signaling cascade that is an important component of neuronal cell death (Pal et al., 2004; Redman et al., 2009b; McCord and Aizenman, 2014; Shah and Aizenman, 2014). This review is intended as a retrospective of our own collaborative work rather than a comprehensive overview of the redox biology of excitotoxic phenomena. As such, we sincerely apologize in advance to all of our colleagues who have made significant contributions to this research topic but whom we have failed to cite.
The NMDA Receptor Redox Modulatory Site
Background
The NMDA appears to have been assembled in the course of evolution by tethering bacterial periplasmic amino acid-binding proteins onto an inside out potassium-like channel (Traynelis et al., 2010). This receptor is not only a gateway to long-term changes in synaptic function, but, strikingly, also a mediator of neuronal cell death (Hansen et al., 2017). Indeed, unregulated activation of this receptor is a major component of excitotoxicity (Foster et al., 1983; Choi et al., 1989), the aptly worded cell death process coined by the late John Olney, as a result of his work on glutamate neurotoxicity (Blood et al., 1969; Olney, 1969; Olney and Sharpe, 1969) following earlier observations by Lucas and Newhouse (1957). It is this potentially lethal risk of overactivity of NMDA receptors that may have contributed to the endowment of this ligand-gated channel with a profusion of modulatory domains. Zinc, protons, magnesium, glycine, polyamines, membrane surface tension, and even light comprise a partial list of known regulators of NMDA receptor function (Paoletti and Ascher, 1994; Leszkiewicz et al., 2000; Hansen et al., 2018). Our own work, first reported over 30 years ago, added another important component to this list, namely, redox-active agents (Aizenman et al., 1989). Through the years, many of these forms of NMDA receptor regulation, including the redox modulatory site (Jensen et al., 1994; Sanchez et al., 2000), have provided enticing, if ultimately frustrating, targets for the pharmacological alleviation of excitotoxic cell death. Below, we describe the studies that led to the discovery of the redox site as well as key observations from our laboratories that followed this finding.
Redox Revealed
In the mid-1980s, two of the authors (EA and RL) began a collaborative effort aimed at biochemically isolating putative neuronal nicotinic receptors from the chick retina. Although at the time nicotinic receptors were widely appreciated to exist in the CNS, their now known complex molecular identity had just begun to be elucidated (Boulter et al., 1987; Goldman et al., 1987; Whiting et al., 1987). One of us (RL) had previously isolated a fraction of the venom from the banded krait Bungarus multicinctus (toxin F, later known as κ-bungarotoxin), which could act as a potential high affinity ligand for the immunoprecipitation of acetylcholine receptors from solubilized chick retinal membranes (Loring et al., 1984, 1986, 1989; Loring and Zigmond, 1988). Unfortunately, we found that virtually every detergent utilized in our studies promptly disrupted the binding site for the toxin, and therefore we turned our attention to isolating the receptor by affinity alkylation. This plan was based on earlier work by Arthur Karlin and colleagues describing the presence of redox-labile vicinal cysteine residues at the agonist binding site of the alpha subunit of the muscle nicotinic receptor (Karlin and Winnik, 1968; Karlin, 1969; Kao and Karlin, 1986). To confirm that the nicotinic receptors present in the chick retina contained redox-sensitive moieties similar to muscle receptors, we first monitored trans-retinal electrical activity following drug application to the retina, using the convenient hemisected chick eyeball as a perfusion chamber (Figure 1A). As anticipated, responses evoked by the selective nicotinic agonist 1,1-dimethyl-4-phenyl-piperazinium iodide (DMPP) were essentially abolished following a 2-min application of the reducing agent dithiothreitol (DTT), an effect reversible by a subsequent treatment with the thiol oxidizing agent 5,5’-dithio-bis-nitrobenzoic acid (DTNB) (Figure 1B). To control for potential deleterious actions of the thiol agents on the preparation, we utilized what we had thought would be a proper control, an excitatory agonist acting at a different receptor, likely not affected by redox agents. To our surprise, responses evoked by the glutamate receptor agonist N-methyl-D-aspartate (NMDA) were extremely sensitive to redox agents, and actually behaved in the opposite direction to those triggered by DMPP: DTT dramatically potentiated the electrical responses to NMDA, while DTNB nearly completely inhibited them (Figure 1B) (Aizenman et al., 1989).
FIGURE 1
The experiments that followed this finding essentially took three main directions of study. One path aimed to define the actions of redox agents on the intrinsic properties of the NMDA receptor while attempting to identify the molecular identity of the thiol reactive moieties within the protein. The second path was directed at identifying potentially endogenous modulators of the redox modulatory site. The third path aimed to establish the relevance of the site for NMDA receptor-mediated pathophysiological cellular processes. The results of these three research programs are briefly summarized below.
Functional Properties of Redox Modulation of the NMDA Receptor
In addition to chick retina recordings, our initial study, conducted in the laboratories of Richard Zigmond and Stuart Lipton, also evaluated NMDA receptor-mediated whole cell currents in cultured rat cortical neurons under reducing and oxidizing conditions. We noted no changes in extracellular magnesium or zinc block, and no overt changes to the current–voltage relationship of the currents (Aizenman et al., 1989). The Reynolds and Aizenman laboratories quickly followed with a study that represented the first of a long string of collaborative redox studies between the two groups (Reynolds et al., 1990). We found that reducing and oxidizing conditions could effectively increase or decrease overall levels of glutamate, glycine, and spermidine-stimulated binding of the NMDA receptor channel blocker [3H]-MK801 to rat brain membranes, without any observable changes in the affinity of any of these agents. Moreover, redox agents did not affect the binding affinity of NMDA receptor competitive antagonists. We also observed dramatic enhancements in NMDA-stimulated intracellular calcium responses following DTT treatment. A detailed analysis of the redox properties of the NMDA receptor was then performed, utilizing whole-cell patch clamp recording in cortical neurons in tissue culture (Tang and Aizenman, 1993a). Here, we defined the time and concentration-dependence for reduction and oxidation of the receptor. Most informatively, we showed that the actions of redox agents on native NMDA receptors in neurons could be observed at the single channel level, primarily as a change in open channel frequency. Lastly, we were able to demonstrate that following reduction, the NMDA receptor could be “locked” in a potentiated state by utilizing the alkylating agent n-ethylmaleimide (Tang and Aizenman, 1993b). A follow-up study examined the voltage-dependence of reduction and oxidation, where we observed that reduction was much more effective at negative holding voltages in whole cell patch-clamped cortical neurons (Tang and Aizenman, 1993c). Interestingly, sequential reduction and oxidation at positive potentials led to long-lasting changes in the mean open time of receptor channels (Tang and Aizenman, 1993b).
Subunit Localization of Redox Modulatory Sites of the NMDA Receptor
A study by Sullivan et al. (1994) was the first to identify two extracellular cysteine residues within the GluN1 subunit that were critical for imparting redox sensitivity to heteromeric receptors assembled with GluN2B, GluN2C, or GluN2D subunits, but not GluN2A. This study suggested that GluN2A contained an additional redox-sensitive moiety, which our group later found to be sufficient for the modulation of GluN1/GluN2A receptors (Brimecombe et al., 1999), and selectively modified by cyanide, a known reducing agent (Arden et al., 1998). Work by Stuart Lipton and co-workers associated the GluN2A redox site, which was also extracellular, to the high sensitivity of this subunit to the metal zinc (Choi et al., 2001). We performed a series of single channel studies in recombinant NMDA receptors expressed in Chinese hamster ovary cells (Boeckman and Aizenman, 1994, 1996; Blanpied et al., 1997) to characterize in detail the roles the various receptor subunits played in redox modulation (Brimecombe et al., 1997). Reduction increases open channel frequency in all receptor combinations tested (GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C), but only GluN2A-containing receptors had redox-dependent changes in open dwell-time (Figure 2). As a final note in this section, the two redox sensitive cysteine residues in GluN1 (Sullivan et al., 1994) were essential for imparting NMDA receptors with light sensitivity (Leszkiewicz et al., 2000, 2002), even in receptors containing the GluN2A subunit (Leszkiewicz and Aizenman, 2002). These studies revealed many opportunities for fine-tuning NMDA receptor responses by redox modulation, in a subunit-specific manner.
FIGURE 2
Endogenous Modulators of the NMDA Redox Site
During our initial studies, we observed an intrinsic variability in the redox state of native NMDA receptors, such that in some cells the initial DTT potentiation was modest, with a subsequent, very pronounced inhibitory effect of DTNB; in most cells, however, the initial effect of the reductant was most pronounced (Aizenman et al., 1989). This suggested to us the possibility that endogenous thiol-reactive agents could be present in our preparations. Indeed, we soon discovered that redox-active oxygen-derived free radicals were highly effective at modifying NMDA receptor function (Aizenman et al., 1990a; Aizenman, 1995). The list of potential endogenous modulators of the redox site grew rapidly. Oxidized glutathione (Gilbert et al., 1991), the essential nutrient pyrroloquinoline quinone (PQQ) (Aizenman et al., 1992b, 1994; Scanlon et al., 1997), dihydrolipoic and lipoic acid (Tang and Aizenman, 1993a), as well as singlet oxygen (Eisenman et al., 2009), were all shown to interact with the redox site and influence NMDA receptor function.
Our group found that nitric oxide (NO) could, under certain conditions, modify NMDA receptor physiological responses (Hoyt et al., 1992). Stuart Lipton and colleagues (Lei et al., 1992) reported that the effects of NO were, in fact, mediated via the modification of the NMDA receptor redox site. This conclusion was based on the observation that NO donors produced an attenuated inhibition in reduced and alkylated (“locked”) NMDA receptor-mediated calcium transients. In direct contrast to these findings, Joel Bockaert and colleagues noted that reduced and alkylated NMDA receptor-mediated whole-cell currents were still sensitive to NO donors, suggesting a lack of effect on the redox site (Fagni et al., 1995). In agreement with these findings, results from our group, utilizing recombinantly expressed wild-type and mutant GluN1 receptors lacking a redox site (Figure 3), established that the redox site was likely not the primary target of the reactive nitrogen species (Aizenman et al., 1998; Aizenman and Potthoff, 1999). Most importantly, later studies by John Garthwaite and colleagues indicated that physiological levels of NO did not influence NMDA receptor function to any extent (Hopper et al., 2004).
FIGURE 3
Redox Modulation of NMDA Excitotoxicity
A number of thiol oxidizing agents acting at the redox site proved to be strongly neuroprotective against NMDA receptor-mediated excitotoxic injury, including the seleno-organic compound ebselen (Herin et al., 2001). Moreover, sub-lethal concentrations of oxygen-derived free radicals also limited NMDA toxicity, leading us to postulate that endogenously generated reactive species, acting via the redox modulatory site, may serve a neuroprotective role during tissue reperfusion following cerebral ischemia (Aizenman et al., 1990a). In contrast to oxidizing agents, reducing agents, such as DTT, potentiated NMDA excitotoxicity, an effect that could be completely blocked by antagonists of the NMDA receptor (Aizenman and Hartnett, 1992). Finally, our group provided evidence that changes in NMDA receptor redox sensitivity may be partly responsible for developmental changes in excitotoxic susceptibility in cortical neurons in tissue culture (Sinor et al., 1997). We noted that the NMDA receptor in immature neurons tended to prefer an oxidized basal state, while in mature neurons, the resting state of the receptor tended to rest in a more reduced state. Immature neurons, which are normally fairly resistant to NMDA toxicity, could thus be rendered sensitive to injury by the addition of a reducing agent (Sinor et al., 1997).
In the late 1980s, Paul Gallop (1927–1996) introduced the redox cycling quinone PQQ to two of us (PR and EA) while we were using an instrument in his well-equipped laboratory. Paul was a brilliant, engaging, kind, and generous Harvard biochemist. At the time we met him, PQQ seemed to occupy the forefront of his research efforts. This compound had been described as an essential nutrient, proposed to be a co-factor in many enzymatic redox reactions in a wide range of tissues (Gallop et al., 1989; Bishop et al., 1998). Paul suggested to us that PQQ may act as a strong modulator of the NMDA redox site, which was indeed the case (Aizenman et al., 1992b, 1994; Scanlon et al., 1997). Importantly, PQQ proved to be strongly neuroprotective, not only against excitotoxic injury in in vitro preparations (Aizenman et al., 1992b), but also in in vivo models of both stroke and epilepsy, as we showed in a series of studies in collaboration with Frances Jensen (Jensen et al., 1994; Sanchez et al., 2000). Unfortunately, during that time, the NMDA receptor as a drug target in human stroke had been losing favor due a series of failed clinical trials of NMDA receptor antagonists, and the emergence of data suggesting that some these agents produce a vacuolar degeneration (Olney et al., 1991; Fix et al., 1993; Ikonomidou and Turski, 2002; Hoyte et al., 2004). There remains the possibility that redox modulation of the NMDA receptor, as distinguished from receptor blockade, would offer an effective approach without the pathological consequences. Our work in this area was an exciting endeavor in which a chance discovery, followed by intensive mechanistic studies, led to a potentially translatable drug class. It is also noteworthy that work by other investigators over the years has provided important links between the NMDA redox site and a wide range of physiological and pathological processes in the brain, including NMDA receptor-mediated synaptic current long-term potentiation (Gozlan et al., 1995), NMDA receptor hypofunction in schizophrenia (Steullet et al., 2016), as well as synaptic dysfunction in aging and Alzheimer’s disease (Foster et al., 2017).
TOPA Quinone, a Catechol-Derived Excitotoxin
A Historical Perspective
From the late 1950s to the mid-1970s, Jeffrey Watkins and colleagues carried out a series of groundbreaking studies using amphibian and mammalian spinal cord preparations to test a large number of small molecules as potential excitatory and inhibitory neural substances. A powerful and now well know excitant resulting of this search was, of course, glutamate (Curtis et al., 1959). And, as they say, the rest is history (Watkins and Jane, 2006). But among some of the many compounds evaluated, these investigators noted that both L-3,4-dihydroxyphenylalanine (L-DOPA) and its hydroxylated derivative L-2,4,5-trihydroxyphenylalanine (6-hydroxydopa, or TOPA), could also elicit excitatory activity in their preparations (Biscoe et al., 1976). These observations were of special interest, given the known inherent instability and neurotoxicity of oxidant-prone catechols such as dopamine (Graham, 1978; Rosenberg, 1988) and concerns about the possibility that L-DOPA or levodopa, the most important treatment for Parkinson’s disease, might itself be the cause of neurodegeneration in populations of dopaminergic and non-dopaminergic neurons (Bonnet et al., 1987; Fahn, 1996; Agid et al., 1998).
At approximately the same time that PAR was studying the toxic potential of catecholamines to CNS neurons in culture (Rosenberg, 1988), we began our collaboration with a study that revealed the extreme sensitivity of CNS neurons to excitotoxicity (Rosenberg and Aizenman, 1989) (Figure 4). Remarkably, when neurons were grown in culture without astrocytes, L-glutamate was found to have an LD50 (concentration at which 50% of neurons are killed following treatment) in the micromolar concentration range, a degree of vulnerability to the toxic effects of glutamate that had not been previously appreciated (Rosenberg et al., 1992; Lipton and Rosenberg, 1994). It was recognized that there may be multiple mechanisms responsible for the influence of astrocytes on the potency of glutamate as an excitotoxin. We established that NMDA receptor-mediated currents were unaffected by the presence or absence of astrocytes (Rosenberg and Aizenman, 1989). In addition, NMDA receptor agonists that were not substrates for glutamate transporters, including NMDA itself, had virtually identical excitotoxic potencies regardless of the culture type (Rosenberg et al., 1992). This work, along with observations by Garthwaite et al. (1992), demonstrated that glutamate uptake was a critical determinant of neuronal survival in the mammalian CNS. Moreover, our work established that the pharmacology of NMDA receptor-mediated toxicity, specifically regarding the potency of agonists, was similar to the pharmacology of the NMDA receptor characterized by measuring NMDA mediated physiological responses and binding studies (Rosenberg et al., 1992). This conclusion had been previously missed in previous work on excitotoxicity that did not take into account the effects of glutamate uptake on the interaction of glutamate agonists with their receptors, as had been anticipated by Garthwaite (1985). In 1992, the three major glutamate transporters of the forebrain were cloned, including EAAC1 (Kanai and Hediger, 1992), GLAST (Storck et al., 1992), and GLT-1 (Pines et al., 1992), which represent approximately 1% of total protein in the forebrain (Lehre and Danbolt, 1998). Although GLT-1 for over a decade after its discovery was assumed to be expressed exclusively in astrocytes (Rimmele and Rosenberg, 2016), it was ultimately shown to be the primary glutamate transporter expressed in axon terminals (Chen et al., 2004; Petr et al., 2015) where it serves an important metabolic function in providing glutamate as a substrate for synaptic mitochondria (McNair et al., 2020). Recent work has strongly implicated GLT-1 in the pathogenesis of Alzheimer’s disease (Sharma et al., 2019; Zott et al., 2019) emphasizing the importance of understanding the fine regulation of the concentrations of glutamate and other glutamate agonists in and around synapses.
FIGURE 4
We were thus open to the possibility that even low-level production of the glutamate receptor agonist TOPA by oxidation of L-DOPA in situ might be a significant cause of excitotoxic neurodegeneration. In collaboration with RHL, we were able to demonstrate that, in our hands, freshly prepared DOPA itself was not an excitant (Newcomer et al., 1995a) while TOPA was an efficacious excitatory agonist acting at non-NMDA receptors (Aizenman et al., 1990b). Of note, while we were enduring a lengthy and tortuous review process of our manuscript, Olney et al. (1990) reported excitatory actions of TOPA. In a subsequent, more comprehensive study, we showed that, in fact, an oxidation product of TOPA, putatively TOPA quinone, and not TOPA itself, was the excitatory substance (Rosenberg et al., 1991). As TOPA oxidized into a red-colored quinone product, the ability of the solution to elicit excitatory responses greatly increased (Figure 5). We also found that the oxidized form of TOPA, which was spectrophotometrically distinct from dopachrome, was strongly excitotoxic to cultured rat cultured neurons via non-NMDA receptor activation (Rosenberg et al., 1991). Maintaining TOPA in a reduced state also limited its ability to excite or kill neurons (Rosenberg et al., 1991; Aizenman et al., 1992a). In collaboration with Paul Gallop, we attempted to identify the active species using mass spectrometry but poor volatilization of the amino acid and inability to form stable adducts limited our progress. We thus turned our attention to high-performance liquid chromatography (HPLC) to address this issue.
FIGURE 5
TOPA Quinone
In the mid-1990s, we performed a series of detailed analytical studies using reverse-phase HPLC coupled to a dual electrode coulometric detector to analyze both DOPA and TOPA-containing solutions under a variety of conditions (Newcomer et al., 1993). One of the most striking features of our analysis was the revelation that both TOPA and its autoxidation product TOPA quinone had a much more negative redox potential (−150 mV), when compared to nearly all other catecholamines tested (+200 mV) (Figure 6A). This feature allowed us to set the electrochemical detector at a potential where the chromatogram response would be maximal for TOPA and TOPA quinone, without virtually any interference from any other catechol-derived compound (Figure 6B). We also found that TOPA quinone was the dominant species at physiological pH, and that the conversion of TOPA to TOPA quinone was reversible upon acidification. Importantly, TOPA solutions allowed to oxidize for up to 4 h produced only one major product, with spectrophotometrically distinct profile from all other catecholamine oxidation products, such as dopachrome and dopa quinone (Graham, 1978; Rosenberg et al., 1991). Finally, we showed that DOPA-containing solution could also generate TOPA quinone, a process that we later demonstrated was facilitated by the presence of iron and hydrogen peroxide (Newcomer et al., 1995a) (Figure 7).
FIGURE 6
FIGURE 7
Oxidative Production of TOPA Quinone by a Catecholaminergic Cell
What was missing as evidence to support our initial hypothesis was a demonstration that TOPA could be produced in situ. In the last study from our group on this subject, we showed that PC12 cells, a catecholaminergic cell line derived from rat pheochromocytoma (Greene and Tischler, 1976), were able to generate TOPA quinone under both basal and potassium-stimulated conditions (Newcomer et al., 1995b). Indeed, we were able to detect significant concentrations of both TOPA and TOPA quinone in the extracellular fluid of the cell cultures, a process facilitated by the addition of an inhibitor of DOPA decarboxylase. As no TOPA compounds were detected when glutathione was included in the incubating solution, we concluded that the oxidative conversion of DOPA to TOPA quinone occurred extracellularly. These results suggested that catecholaminergic cells in the brain could, under certain conditions, generate TOPA quinone and lead to excitotoxic injury, a notion reinforced by the fact that a prior lesion of the substantia nigra can protect striatal neurons from ischemia, an insult thought to cause neurodegeneration by excitotoxic processes (Globus et al., 1987). The excitatory and possible toxic consequences of TOPA quinone production continued to be discussed in the literature, many years after our work concluded (Guatteo et al., 2013; Kostrzewa, 2016). Finally, as a final note of interest demonstrating its endogenous production, TOPA quinone was identified as the quinone cofactor of several oxidases, some of which were previously thought to contain PQQ at its active site (Janes et al., 1990; Dove et al., 1996; Dooley, 1999).
Oxidative Liberation of Intracellular Zinc
Zinc Neurotoxicity
In the mid to late 1980s, Jae-young Koh, Dennis Choi, and colleagues showed that a brief exposure to zinc was sufficient to lethally injure cortical neurons in tissue culture and the field of zinc mediated neurodegeneration was born (Yokoyama et al., 1986; Choi et al., 1988). A few years later, Koh and colleagues observed that, following injury, zinc accumulated in vulnerable neurons in the absence of synaptic, or vesicular zinc, suggesting that the metal may have an intracellular source that, in and of itself, would be sufficient to trigger cell death (Lee et al., 2000). Indeed, that same year, two of the authors (EA and IR) provided unequivocal evidence that oxidative liberation of intracellular zinc from metal-binding proteins could induce a neuronal cell death signaling cascade that resembled, in many ways, excitotoxicity, especially in its preference for neurons over glia (Figure 8) (Aizenman et al., 2000). In those initial studies, we utilized the cell-permeant thiol oxidizing agent 2,2′-dithiodipyridine (DTDP) and were able to demonstrate release of zinc from intracellular stores (Figure 9). Many reviews have appeared summarizing our work and that of others on this subject (Pal et al., 2004; Aras and Aizenman, 2011; Sensi et al., 2011; McCord and Aizenman, 2014), including a very recently published book chapter (Aizenman, 2019). As such, we focus here on the specific connections that exist between excitotoxic processes and the liberation of intracellular, mobile zinc.
FIGURE 8
FIGURE 9
Intracellular Zinc Liberation
Zinc can be released from intracellular metal-binding proteins, primarily metallothionein (MT), via redox-mediated processes (Maret, 2019). In fact, MT, in spite of having a very high affinity for zinc (Kd = 1 × 10–14 M at physiological pH), can readily release the metal upon mild oxidative conditions (−365 mV redox potential) (Maret and Vallee, 1998). Wolfgang Maret, Bert Vallee, and colleagues utilized DTDP to oxidize zinc-coordinating residues within MT and release its bound zinc (Maret et al., 1997; Jacob et al., 1998; Jiang et al., 1998; Maret and Vallee, 1998). This work alerted us to the possibility that DTDP was lethally injuring neurons by inducing zinc release, rather than by a triggering a calcium-dependent process, which would have been the more obvious choice given the prominent role assigned to calcium in excitotoxic neurodegeneration (Aizenman et al., 2000). In fact, we had initially hypothesized that the lethal actions of the oxidizing agent were being mediated by release of calcium from the endoplasmic reticulum following oxidation of the ryanodine receptor, as reported to occur in cardiac myocytes by Prabhu and Salama (1990). We were initially led astray by the promiscuous divalent cation binding ability of most calcium indicators (Grynkiewicz et al., 1985), but ultimately demonstrated the critical role of mobilization of free zinc (Aizenman et al., 2000). We now know that MT, especially MT3, the primary isoform in neurons (Hidalgo et al., 2001; Vasak and Meloni, 2017), represents a critical source of intracellular zinc in injured neurons (Lee et al., 2003), can serve both as a source and a buffer of intracellular zinc in astrocytes (Malaiyandi et al., 2004), and is a key and highly regulated component of cell death signaling pathways triggered by the metal (Sensi et al., 2003; Aras et al., 2009a; Medvedeva et al., 2017). However, with an estimated 2800 zinc binding proteins in the human proteome (Andreini et al., 2006), there is clearly the possibility of a multitude of proteins contributing to an intracellular zinc response.
Linking Excitotoxic Stimuli, Intracellular Zinc Release, and Neuronal Dysfunction
Intracellular zinc release in neurons can be induced by a variety of stimuli in addition to DTDP. These include peroxynitrite (Zhang et al., 2004, 2006; Knoch et al., 2008), ischemic injury (Aras et al., 2009b), and, importantly, glutamate (Aras et al., 2009a). As glutamate can also generate the production of reactive oxygen species via NMDA receptor activation (Reynolds and Hastings, 1995), by simultaneously measuring calcium and zinc transients in neurons (Figure 10), the Reynolds laboratory provided unequivocal evidence that NMDA receptor stimulation leads to a calcium-dependent production of free radicals, both cytoplasmic and mitochondrial in origin, which, in turn, led to the liberation of intracellular zinc (Dineley et al., 2008). This finding, and subsequent work by us and other groups (Granzotto and Sensi, 2015; Yeh et al., 2017, 2019), provided a critical link between excitotoxic processes and intracellular liberated zinc-dependent cell injurious signaling cascades. Zinc translocation from presynaptic, zinc containing terminals to postsynaptic cells via calcium-permeable channels (Sensi et al., 1999a, b) can, under certain conditions, also contribute to the deleterious actions of the metal (Medvedeva et al., 2017). Of note, increases in intracellular zinc can lead to subsequent additional calcium-dependent processes that significantly contribute to neuronal death-inducing cellular pathways (Vander Jagt et al., 2009; McCord and Aizenman, 2013).
FIGURE 10
In addition to the generation of reactive oxygen species, dysregulated intracellular zinc has other well-known effects on mitochondrial function, including alterations in mitochondrial membrane potential (Sensi et al., 2000, 2003; He and Aizenman, 2010), altered trafficking (Malaiyandi et al., 2005), and mitochondrial channel opening with the subsequent release of pro-apoptotic factors (Jiang et al., 2001; Bonanni et al., 2006). However, activation of apoptotic signals requires the loss of cytoplasmic potassium, providing a requisite, optimum environment for protease and nuclease activation (Bortner et al., 1997; Hughes et al., 1997; Hughes and Cidlowski, 1999; Montague et al., 1999). Our group thus began an investigation to evaluate whether cellular potassium efflux was also required for intracellular zinc-mediated cell death, and if so, what cell signaling components were activated to accomplish this result.
A Zinc-Potassium Continuum in Neuronal Cell Death
Neurons exposed to DTDP were monitored for the enhancement of potassium currents as had been reported by Yu et al. (1997) in serum-deprived and staurosporine treated cells destined for apoptotic cell death. We observed a remarkable enhancement in delayed-rectifier, tetraethylammonium (TEA)-sensitive potassium currents approximately 3 h after a brief DTDP exposure (McLaughlin et al., 2001) (Figure 11). The potassium current surge could be blocked by zinc chelation and p38 MAPK inhibitors, but not by caspase inhibitors. However, all of these three treatments, in addition to TEA, could block DTDP toxicity, suggesting that zinc and p38 were upstream of the enhanced potassium currents, later identified as being mediated by the delayed rectifier potassium channel Kv2.1 (Pal et al., 2003). Additional studies revealed that the apoptotic potassium current surge results from a zinc-activated phosphorylation of Kv2.1 by both Src and p38, which in turn, induces a syntaxin-dependent de novo insertion of large number of Kv2.1 channels into the plasma membrane (Pal et al., 2006; Redman et al., 2007, 2009a; McCord et al., 2014). The characterization of this cell death-enabling pathway led to the generation of a new generation of neuroprotective compounds for the treatment of neurodegenerative disorders in which excitotoxicity has been proposed to play a prominent role, including cerebral ischemia-reperfusion injury (Yeh et al., 2017, 2019). The efficacy of these agents suggests either that the zinc mobilizing pathway that we have delineated and the excitotoxic pathway are both independently active in ischemic injury, or that these two pathways are intimately linked. Finally, it must be noted that zinc-triggered cell death pathways are not always apoptotic in nature, nor dependent on potassium efflux. For example, we observed that the neurotoxic action of the biocide methylisothiazolinone is also mediated through intracellular zinc liberation, in this case resulting in ERK activation and caspase-independent cell death (Du et al., 2002). In addition, Lee and Koh (2010) have reported that oxidative liberation of intracellular zinc can also lead to lysosomal dysfunction and autophagy in neurons and astrocytes.
FIGURE 11
Concluding Remarks
In this article, we have looked back over 30 years of collaborative work on many aspects of redox processes important in neurodegeneration. Writing this review has provided the occasion for assessing the impact our research has had not only on the field of excitotoxicity, but also on neuroscience in general. Importantly, it has stimulated us to think about where the field is now, and what there might be left to contribute. Clearly, what is missing from the field of excitotoxicity in general is the translation of an enormous body of work into useful clinical drugs to halt or limit neuronal cell death. This has been, admittedly, a very difficult problem, to which large amounts of financial resources and numerous careers have been devoted. Our own recent work points to new therapeutic avenues to pursue, targeting Kv2.1-mediated potassium efflux in cell death processes (Yeh et al., 2017, 2019; Schulien et al., 2020). Although ameliorating excitotoxic injury and clinical disability has been very challenging, a better appreciation of critical mechanisms can only improve the potential to succeed in addressing this important unmet medical need. Regardless of any potential future developments, however, we feel our past and current interactions, and the work that has resulted from our many collaborative efforts, have been highly stimulating, intellectually rewarding, but, most importantly, incredibly fun. Here is looking at the next 50 years of excitotoxicity research!
Statements
Author contributions
All authors contributed to the writing of this review article.
Funding
The work described here has been funded by several grants to the authors over the years, many of which have long expired, although prior long-term support from NIH grant NS029365 (Redox modulation of NMDA receptors) to EA must be gratefully acknowledged. Most recent, currently active funding has been from NIH grant NS043277 to EA and NIH grant EY027881 to PR, and NIH grant HD018655.
Acknowledgments
We would like to thank all the students, postdoctoral fellows, and research faculty in the authors’ laboratories that have participated in the work described here over the last 30 years. A very special thank you to Ms. Karen Hartnett-Scott, the manager of the Aizenman laboratory for over three decades, whose dedication and countless contributions have been essential to a large portion of the work presented in this review.
Conflict of interest
IR is employed by company Rewind Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AgidY.ChaseT.MarsdenD. (1998). Adverse reactions to levodopa: Drug toxicity or progression of disease?Lancet351851–852. 10.1016/s0140-6736(05)70285-3
2
AizenmanE. (1995). Modulation of N-methyl-D-aspartate receptors by hydroxyl radicals in rat cortical neurons in vitro.Neurosci. Lett.18957–59. 10.1016/0304-3940(95)11442-y
3
AizenmanE. (2019). “Zinc signaling in the life and death of neurons,” in Zinc Signaling, edsFukadaT.KambeT. (Singapore: Springer), 165–185. 10.1007/978-981-15-0557-7_9
4
AizenmanE.BoeckmanF. A.RosenbergP. A. (1992a). Glutathione prevents 2,4,5-trihydroxyphenylalanine excitotoxicity by maintaining it in a reduced, non-active form.Neurosci. Lett.144233–236. 10.1016/0304-3940(92)90757-x
5
AizenmanE.BrimecombeJ. C.PotthoffW. K.RosenbergP. A. (1998). Why is the role of nitric oxide in NMDA receptor function and dysfunction so controversial?Prog. Brain Res.11853–71. 10.1016/s0079-6123(08)63200-8
6
AizenmanE.HartnettK. A. (1992). The action of CGS-19755 on the redox enhancement of NMDA toxicity in rat cortical neurons in vitro.Brain Res.58528–34. 10.1016/0006-8993(92)91187-j
7
AizenmanE.HartnettK. A.ReynoldsI. J. (1990a). Oxygen free radicals regulate NMDA receptor function via a redox modulatory site.Neuron5841–846. 10.1016/0896-6273(90)90343-e
8
AizenmanE.HartnettK. A.ZhongC.GallopP. M.RosenbergP. A. (1992b). Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site.J. Neurosci.122362–2369. 10.1523/jneurosci.12-06-02362.1992
9
AizenmanE.JensenF. E.GallopP. M.RosenbergP. A.TangL. H. (1994). Further evidence that pyrroloquinoline quinone interacts with the N-methyl-D-aspartate receptor redox site in rat cortical neurons in vitro.Neurosci. Lett.168189–192. 10.1016/0304-3940(94)90447-2
10
AizenmanE.LiptonS. A.LoringR. H. (1989). Selective modulation of NMDA responses by reduction and oxidation.Neuron21257–1263. 10.1016/0896-6273(89)90310-3
11
AizenmanE.PotthoffW. K. (1999). Lack of interaction between nitric oxide and the redox modulatory site of the NMDA receptor.Br. J. Pharmacol.126296–300. 10.1038/sj.bjp.0702295
12
AizenmanE.ReynoldsI. J. (1992). Modulation of NMDA excitotoxicity by redox reagents.Ann. N. Y. Acad. Sci.648125–131. 10.1111/j.1749-6632.1992.tb24530.x
13
AizenmanE.StoutA. K.HartnettK. A.DineleyK. E.McLaughlinB.ReynoldsI. J. (2000). Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release.J. Neurochem.751878–1888. 10.1046/j.1471-4159.2000.0751878.x
14
AizenmanE.WhiteW. F.LoringR. H.RosenbergP. A. (1990b). A 3,4-dihydroxyphenylalanine oxidation product is a non-N-methyl-D-aspartate glutamatergic agonist in rat cortical neurons.Neurosci. Lett.116168–171. 10.1016/0304-3940(90)90404-w
15
AndreiniC.BanciL.BertiniI.RosatoA. (2006). Counting the zinc-proteins encoded in the human genome.J. Proteome Res.5196–201. 10.1021/pr050361j
16
ArasM. A.AizenmanE. (2011). Redox regulation of intracellular zinc: molecular signaling in the life and death of neurons.Antioxid. Redox Signal.152249–2263. 10.1089/ars.2010.3607
17
ArasM. A.HaraH.HartnettK. A.KandlerK.AizenmanE. (2009a). Protein kinase C regulation of neuronal zinc signaling mediates survival during preconditioning.J. Neurochem.110106–117. 10.1111/j.1471-4159.2009.06106.x
18
ArasM. A.HartnettK. A.AizenmanE. (2008). Assessment of cell viability in primary neuronal cultures.Curr. Protoc. Neurosci.Chapter 7:Unit7.18.
19
ArasM. A.SaadiR. A.AizenmanE. (2009b). Zn2+ regulates Kv2.1 voltage-dependent gating and localization following ischemia.Eur. J. Neurosci.302250–2257. 10.1111/j.1460-9568.2009.07026.x
20
ArdenS. R.SinorJ. D.PotthoffW. K.AizenmanE. (1998). Subunit-specific interactions of cyanide with the N-methyl-D-aspartate receptor.J. Biol. Chem.27321505–21511. 10.1074/jbc.273.34.21505
21
BiscoeT. J.EvansR. H.HeadleyP. M.MartinM. R.WatkinsJ. C. (1976). Structure-activity relations of excitatory amino acids on frog and rat spinal neurones.Br. J. Pharmacol.58373–382. 10.1111/j.1476-5381.1976.tb07714.x
22
BishopA.GallopP. M.KarnovskyM. L. (1998). Pyrroloquinoline quinone: A novel vitamin?Nutr. Rev.56287–293. 10.1111/j.1753-4887.1998.tb01661.x
23
BlanpiedT. A.BoeckmanF. A.AizenmanE.JohnsonJ. W. (1997). Trapping channel block of NMDA-activated responses by amantadine and memantine.J. Neurophysiol.77309–323. 10.1152/jn.1997.77.1.309
24
BloodF. R.OserB. L.WhiteP. L.OlneyJ. W. (1969). Monosodium glutamate.Science1651028–1029.
25
BoeckmanF. A.AizenmanE. (1994). Stable transfection of the NR1 subunit in Chinese hamster ovary cells fails to produce a functional N-methyl-D-aspartate receptor.Neurosci. Lett.173189–192. 10.1016/0304-3940(94)90180-5
26
BoeckmanF. A.AizenmanE. (1996). Pharmacological properties of acquired excitotoxicity in Chinese hamster ovary cells transfected with N-methyl-D-aspartate receptor subunits.J. Pharmacol. Exp. Ther.279515–523.
27
BonanniL.ChacharM.Jover-MengualT.LiH.JonesA.YokotaH.et al (2006). Zinc-dependent multi-conductance channel activity in mitochondria isolated from ischemic brain.J. Neurosci.266851–6862. 10.1523/jneurosci.5444-05.2006
28
BonnetA. M.LoriaY.Saint-HilaireM. H.LhermitteF.AgidY. (1987). Does long-term aggravation of Parkinson’s disease result from nondopaminergic lesions?Neurology371539–1542.
29
BortnerC. D.HughesF. M.CidlowskiJ. A. (1997). A primary role for K+ and Na+ efflux in the activation of apoptosis.J. Biol. Chem.27232436–32442. 10.1074/jbc.272.51.32436
30
BoulterJ.ConnollyJ.DenerisE.GoldmanD.HeinemannS.PatrickJ. (1987). Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family.Proc. Natl. Acad. Sci. U.S.A.847763–7767. 10.1073/pnas.84.21.7763
31
BrimecombeJ. C.BoeckmanF. A.AizenmanE. (1997). Functional consequences of NR2 subunit composition in single recombinant N-methyl-D-aspartate receptors.Proc. Natl. Acad. Sci. U.S.A.9411019–11024. 10.1073/pnas.94.20.11019
32
BrimecombeJ. C.PotthoffW. K.AizenmanE. (1999). A critical role of the N-methyl-D-aspartate (NMDA) receptor subunit (NR) 2A in the expression of redox sensitivity of NR1/NR2A recombinant NMDA receptors.J. Pharmacol. Exp. Ther.291785–792.
33
ChenW.MahadomrongkulV.BergerU. V.BassanM.DeSilvaT.TanakaK.et al (2004). The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons.J. Neurosci.241136–1148. 10.1523/jneurosci.1586-03.2004
34
ChengC.ReynoldsI. J. (1998). Calcium-sensitive fluorescent dyes can report increases in intracellular free zinc concentration in cultured forebrain neurons.J. Neurochem.712401–2410. 10.1046/j.1471-4159.1998.71062401.x
35
ChoiD. W.ViseskulV.AmirthanayagamM.MonyerH. (1989). Aspartate neurotoxicity on cultured cortical neurons.J. Neurosci. Res.23116–121. 10.1002/jnr.490230115
36
ChoiD. W.YokoyamaM.KohJ. (1988). Zinc neurotoxicity in cortical cell culture.Neuroscience2467–79. 10.1016/0306-4522(88)90312-0
37
ChoiY.ChenH. V.LiptonS. A. (2001). Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor.J. Neurosci.21392–400. 10.1523/jneurosci.21-02-00392.2001
38
CurtisD. R.PhillisJ. W.WatkinsJ. C. (1959). Chemical excitation of spinal neurones.Nature183611–612. 10.1038/183611a0
39
DineleyK. E.DevinneyM. J.IIZeakJ. A.RintoulG. L.ReynoldsI. J. (2008). Glutamate mobilizes [Zn2+] through Ca2+ -dependent reactive oxygen species accumulation.J. Neurochem.1062184–2193.
40
DooleyD. M. (1999). Structure and biogenesis of topaquinone and related cofactors.J. Biol. Inorg. Chem.41–11. 10.1007/s007750050283
41
DoveJ. E.SmithA. J.KucharJ.BrownD. E.DooleyD. M.KlinmanJ. P. (1996). Identification of the quinone cofactor in a lysyl oxidase from Pichia pastoris.FEBS Lett.398231–234. 10.1016/s0014-5793(96)01245-8
42
DuS.McLaughlinB.PalS.AizenmanE. (2002). In vitro neurotoxicity of methylisothiazolinone, a commonly used industrial and household biocide, proceeds via a zinc and extracellular signal-regulated kinase mitogen-activated protein kinase-dependent pathway.J. Neurosci.227408–7416. 10.1523/jneurosci.22-17-07408.2002
43
EisenmanL. N.ShuH. J.WangC.AizenmanE.CoveyD. F.ZorumskiC. F.et al (2009). NMDA potentiation by visible light in the presence of a fluorescent neurosteroid analogue.J. Physiol.5872937–2947. 10.1113/jphysiol.2009.172700
44
ErnsterL.LeeC. P. (1964). Biological Oxidoreductions.Annu. Rev. Biochem.33729–790.
45
FagniL.OlivierM.Lafon-CazalM.BockaertJ. (1995). Involvement of divalent ions in the nitric oxide-induced blockade of N-methyl-D-aspartate receptors in cerebellar granule cells.Mol. Pharmacol.471239–1247.
46
FahnS. (1996). Is levodopa toxic?Neurology47S184–S195.
47
FixA. S.HornJ. W.WightmanK. A.JohnsonC. A.LongG. G.StortsR. W.et al (1993). Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex.Exp. Neurol.123204–215. 10.1006/exnr.1993.1153
48
FosterA. C.CollinsJ. F.SchwarczR. (1983). On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds.Neuropharmacology221331–1342. 10.1016/0028-3908(83)90221-6
49
FosterT. C.KyritsopoulosC.KumarA. (2017). Central role for NMDA receptors in redox mediated impairment of synaptic function during aging and Alzheimer’s disease.Behav. Brain Res.322223–232. 10.1016/j.bbr.2016.05.012
50
GallopP. M.PazM. A.FluckigerR.KaganH. M. (1989). PQQ, the elusive coenzyme.Trends Biochem. Sci.14343–346. 10.1016/0968-0004(89)90169-2
51
GarthwaiteG.WilliamsG. D.GarthwaiteJ. (1992). Glutamate toxicity: an experimental and theoretical analysis.Eur. J. Neurosci.4353–360. 10.1111/j.1460-9568.1992.tb00882.x
52
GarthwaiteJ. (1985). Cellular uptake disguises action of L-glutamate on N-methyl-D-aspartate receptors. with an appendix: diffusion of transported amino acids into brain slices.Br. J. Pharmacol.85297–307. 10.1111/j.1476-5381.1985.tb08860.x
53
GilbertK. R.AizenmanE.ReynoldsI. J. (1991). Oxidized glutathione modulates N-methyl-D-aspartate- and depolarization-induced increases in intracellular Ca2+ in cultured rat forebrain neurons.Neurosci. Lett.13311–14. 10.1016/0304-3940(91)90045-u
54
GlobusM. Y.GinsbergM. D.DietrichW. D.BustoR.ScheinbergP. (1987). Substantia nigra lesion protects against ischemic damage in the striatum.Neurosci. Lett.80251–256. 10.1016/0304-3940(87)90463-0
55
GoldmanD.DenerisE.LuytenW.KochharA.PatrickJ.HeinemannS. (1987). Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system.Cell48965–973. 10.1016/0092-8674(87)90705-7
56
GozlanH.KhazipovR.Ben-AriY. (1995). Multiple forms of long-term potentiation and multiple regulatory sites of N-methyl-D-aspartate receptors: role of the redox site.J. Neurobiol.26360–369. 10.1002/neu.480260308
57
GrahamD. G. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.Mol. Pharmacol.14633–643.
58
GranzottoA.SensiS. L. (2015). Intracellular zinc is a critical intermediate in the excitotoxic cascade.Neurobiol. Dis.8125–37. 10.1016/j.nbd.2015.04.010
59
GreeneL. A.TischlerA. S. (1976). Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.Proc. Natl. Acad. Sci. U.S.A.732424–2428. 10.1073/pnas.73.7.2424
60
GrynkiewiczG.PoenieM.TsienR. Y. (1985). A new generation of Ca2+ indicators with greatly improved fluorescence properties.J. Biol. Chem.2603440–3450.
61
GuatteoE.YeeA.McKearneyJ.CucchiaroniM. L.ArmogidaM.BerrettaN.et al (2013). Dual effects of L-DOPA on nigral dopaminergic neurons.Exp. Neurol.247582–594. 10.1016/j.expneurol.2013.02.009
62
HansenK. B.YiF.PerszykR. E.FurukawaH.WollmuthL. P.GibbA. J.et al (2018). Structure, function, and allosteric modulation of NMDA receptors.J. Gen. Physiol.1501081–1105.
63
HansenK. B.YiF.PerszykR. E.MennitiF. S.TraynelisS. F. (2017). NMDA receptors in the central nervous system.Methods Mol. Biol.16771–80. 10.1007/978-1-4939-7321-7_1
64
HeK.AizenmanE. (2010). ERK signaling leads to mitochondrial dysfunction in extracellular zinc-induced neurotoxicity.J. Neurochem.114452–461. 10.1111/j.1471-4159.2010.06762.x
65
HerinG. A.DuS.AizenmanE. (2001). The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site.J. Neurochem.781307–1314. 10.1046/j.1471-4159.2001.00517.x
66
HidalgoJ.AschnerM.ZattaP.VasakM. (2001). Roles of the metallothionein family of proteins in the central nervous system.Brain Res. Bull.55133–145. 10.1016/s0361-9230(01)00452-x
67
HillR. (1951). Oxidoreduction in chloroplasts.Adv. Enzymol. Relat. Subj. Biochem.121–39. 10.1002/9780470122570.ch1
68
HopperR.LancasterB.GarthwaiteJ. (2004). On the regulation of NMDA receptors by nitric oxide.Eur. J. Neurosci.191675–1682. 10.1111/j.1460-9568.2004.03306.x
69
HoytK. R.TangL. H.AizenmanE.ReynoldsI. J. (1992). Nitric oxide modulates NMDA-induced increases in intracellular Ca2+ in cultured rat forebrain neurons.Brain Res.592310–316. 10.1016/0006-8993(92)91690-g
70
HoyteL.BarberP. A.BuchanA. M.HillM. D. (2004). The rise and fall of NMDA antagonists for ischemic stroke.Curr. Mol. Med.4131–136. 10.2174/1566524043479248
71
HughesF. M.BortnerC. D.PurdyG. D.CidlowskiJ. A. (1997). Intracellular K+ suppresses the activation of apoptosis in lymphocytes.J. Biol. Chem.27230567–30576. 10.1074/jbc.272.48.30567
72
HughesF. M.CidlowskiJ. A. (1999). Potassium is a critical regulator of apoptotic enzymes in vitro and in vivo.Adv. Enzyme Regul.39157–171. 10.1016/s0065-2571(98)00010-7
73
IkonomidouC.TurskiL. (2002). Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?Lancet Neurol.1383–386. 10.1016/s1474-4422(02)00164-3
74
JacobC.MaretW.ValleeB. L. (1998). Control of zinc transfer between thionein, metallothionein, and zinc proteins.Proc. Natl. Acad. Sci. U.S.A.953489–3494. 10.1073/pnas.95.7.3489
75
JanesS. M.MuD.WemmerD.SmithA. J.KaurS.MaltbyD.et al (1990). A new redox cofactor in eukaryotic enzymes: 6-hydroxydopa at the active site of bovine serum amine oxidase.Science248981–987. 10.1126/science.2111581
76
JensenF. E.GardnerG. J.WilliamsA. P.GallopP. M.AizenmanE.RosenbergP. A. (1994). The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury.Neuroscience62399–406. 10.1016/0306-4522(94)90375-1
77
JiangD.SullivanP. G.SensiS. L.StewardO.WeissJ. H. (2001). Zn(2+) induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria.J. Biol. Chem.27647524–47529. 10.1074/jbc.m108834200
78
JiangL. J.MaretW.ValleeB. L. (1998). The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase.Proc. Natl. Acad. Sci. U.S.A.953483–3488. 10.1073/pnas.95.7.3483
79
KanaiY.HedigerM. A. (1992). Primary structure and functional characterization of a high-affinity glutamate transporter.Nature360467–471. 10.1038/360467a0
80
KaoP. N.KarlinA. (1986). Acetylcholine receptor binding site contains a disulfide cross-link between adjacent half-cystinyl residues.J. Biol. Chem.2618085–8088.
81
KarlinA. (1969). Chemical modification of the active site of the acetylcholine receptor.J. Gen. Physiol.54245–264. 10.1085/jgp.54.1.245
82
KarlinA.WinnikM. (1968). Reduction and specific alkylation of the receptor for acetylcholine.Proc. Natl. Acad. Sci. U.S.A.60668–674. 10.1073/pnas.60.2.668
83
KnochM. E.HartnettK. A.HaraH.KandlerK.AizenmanE. (2008). Microglia induce neurotoxicity via intraneuronal Zn2+ release and a K(+) current surge.Glia5689–96. 10.1002/glia.20592
84
KostrzewaR. M. (2016). Perinatal lesioning and lifelong effects of the noradrenergic neurotoxin 6-hydroxydopa.Curr. Top. Behav. Neurosci.2943–50. 10.1007/7854_2015_414
85
LeeJ. Y.ColeT. B.PalmiterR. D.KohJ. Y. (2000). Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: evidence against synaptic vesicle origin.J. Neurosci.20:RC79.
86
LeeJ. Y.KimJ. H.PalmiterR. D.KohJ. Y. (2003). Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury.Exp. Neurol.184337–347. 10.1016/s0014-4886(03)00382-0
87
LeeS. J.KohJ. Y. (2010). Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes.Mol. Brain3:30. 10.1186/1756-6606-3-30
88
LehningerA. L. (1945). Fatty acid oxidation and the Krebs trocarboxylic acid cycle.J. Biol. Chem.161:413.
89
LehreK. P.DanboltN. C. (1998). The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain.J. Neurosci.188751–8757. 10.1523/jneurosci.18-21-08751.1998
90
LeiS. Z.PanZ. H.AggarwalS. K.ChenH. S.HartmanJ.SucherN. J.et al (1992). Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex.Neuron81087–1099. 10.1016/0896-6273(92)90130-6
91
LeszkiewiczD.AizenmanE. (2002). A role for the redox site in the modulation of the NMDA receptor by light.J. Physiol.545435–440. 10.1113/jphysiol.2002.032755
92
LeszkiewiczD. N.KandlerK.AizenmanE. (2000). Enhancement of NMDA receptor-mediated currents by light in rat neurones in vitro.J. Physiol.524(Pt 2), 365–374. 10.1111/j.1469-7793.2000.t01-1-00365.x
93
LeszkiewiczD. N.McLaughlinB. A.AizenmanE. (2002). Protein kinases and light: unlikely partners in a receptor localization puzzle.Physiol. Behav.77533–536. 10.1016/s0031-9384(02)00911-3
94
LiptonS. A.RosenbergP. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders.N. Engl. J. Med.330613–622. 10.1056/nejm199403033300907
95
LoringR. H.AizenmanE.LiptonS. A.ZigmondR. E. (1989). Characterization of nicotinic receptors in chick retina using a snake venom neurotoxin that blocks neuronal nicotinic receptor function.J. Neurosci.92423–2431. 10.1523/jneurosci.09-07-02423.1989
96
LoringR. H.AndrewsD.LaneW.ZigmondR. E. (1986). Amino acid sequence of toxin F, a snake venom toxin that blocks neuronal nicotinic receptors.Brain Res.38530–37. 10.1016/0006-8993(86)91543-x
97
LoringR. H.ChiappinelliV. A.ZigmondR. E.CohenJ. B. (1984). Characterization of a snake venom neurotoxin which blocks nicotinic transmission in the avian ciliary ganglion.Neuroscience11989–999. 10.1016/0306-4522(84)90209-4
98
LoringR. H.ZigmondR. E. (1988). Characterization of neuronal nicotinic receptors by snake venom neurotoxins.Trends Neurosci.1173–78. 10.1016/0166-2236(88)90168-3
99
LucasD. R.NewhouseJ. P. (1957). The toxic effect of sodium L-glutamate on the inner layers of the retina.AMA Arch. Ophthalmol.58193–201. 10.1001/archopht.1957.00940010205006
100
MalaiyandiL. M.DineleyK. E.ReynoldsI. J. (2004). Divergent consequences arise from metallothionein overexpression in astrocytes: zinc buffering and oxidant-induced zinc release.Glia45346–353. 10.1002/glia.10332
101
MalaiyandiL. M.HonickA. S.RintoulG. L.WangQ. J.ReynoldsI. J. (2005). Zn2+ inhibits mitochondrial movement in neurons by phosphatidylinositol 3-kinase activation.J. Neurosci.259507–9514. 10.1523/jneurosci.0868-05.2005
102
MaretW. (2019). The redox biology of redox-inert zinc ions.Free Radic. Biol. Med.134311–326. 10.1016/j.freeradbiomed.2019.01.006
103
MaretW.LarsenK. S.ValleeB. L. (1997). Coordination dynamics of biological zinc “clusters” in metallothioneins and in the DNA-binding domain of the transcription factor Gal4.Proc. Natl. Acad. Sci. U.S.A.942233–2237. 10.1073/pnas.94.6.2233
104
MaretW.ValleeB. L. (1998). Thiolate ligands in metallothionein confer redox activity on zinc clusters.Proc. Natl. Acad. Sci. U.S.A.953478–3482. 10.1073/pnas.95.7.3478
105
McCordM. C.AizenmanE. (2013). Convergent Ca2+ and Zn2+ signaling regulates apoptotic Kv2.1 K+ currents.Proc. Natl. Acad. Sci. U.S.A.11013988–13993. 10.1073/pnas.1306238110
106
McCordM. C.AizenmanE. (2014). The role of intracellular zinc release in aging, oxidative stress, and Alzheimer’s disease.Front. Aging Neurosci.6:77. 10.3389/fnagi.2014.00077
107
McCordM. C.KullmannP. H.HeK.HartnettK. A.HornJ. P.LotanI.et al (2014). Syntaxin-binding domain of Kv2.1 is essential for the expression of apoptotic K+ currents.J. Physiol.5923511–3521. 10.1113/jphysiol.2014.276964
108
McLaughlinB.PalS.TranM. P.ParsonsA. A.BaroneF. C.ErhardtJ. A.et al (2001). p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis.J. Neurosci.213303–3311. 10.1523/jneurosci.21-10-03303.2001
109
McNairL. F.AndersenJ. V.NissenJ. D.SunY.FischerK. D.HodgsonN. W.et al (2020). Conditional knockout of GLT-1 in neurons leads to alterations in aspartate homeostasis and synaptic mitochondrial metabolism in striatum and hippocampus.Neurochem. Res.451420–1437. 10.1007/s11064-020-03000-7
110
MedvedevaY. V.JiS. G.YinH. Z.WeissJ. H. (2017). Differential vulnerability of CA1 versus CA3 pyramidal neurons after ischemia: possible relationship to sources of Zn2+ accumulation and its entry into and prolonged effects on mitochondria.J. Neurosci.37726–737. 10.1523/jneurosci.3270-16.2016
111
MontagueJ. W.BortnerC. D.HughesF. M.CidlowskiJ. A. (1999). A necessary role for reduced intracellular potassium during the DNA degradation phase of apoptosis.Steroids64563–569. 10.1016/s0039-128x(99)00034-3
112
NewcomerT. A.PalmerA. M.RosenbergP. A.AizenmanE. (1993). Nonenzymatic conversion of 3,4-dihydroxyphenylalanine to 2,4,5-trihydroxyphenylalanine and 2,4,5-trihydroxyphenylalanine quinone in physiological solutions.J. Neurochem.61911–920. 10.1111/j.1471-4159.1993.tb03602.x
113
NewcomerT. A.RosenbergP. A.AizenmanE. (1995a). Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin.J. Neurochem.641742–1748. 10.1046/j.1471-4159.1995.64041742.x
114
NewcomerT. A.RosenbergP. A.AizenmanE. (1995b). TOPA quinone, a kainate-like agonist and excitotoxin is generated by a catecholaminergic cell line.J. Neurosci.153172–3177. 10.1523/jneurosci.15-04-03172.1995
115
OlneyJ. W. (1969). Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate.Science164719–721. 10.1126/science.164.3880.719
116
OlneyJ. W.LabruyereJ.WangG.WozniakD. F.PriceM. T.SesmaM. A. (1991). NMDA antagonist neurotoxicity: mechanism and prevention.Science2541515–1518. 10.1126/science.1835799
117
OlneyJ. W.SharpeL. G. (1969). Brain lesions in an infant rhesus monkey treated with monsodium glutamate.Science166386–388. 10.1126/science.166.3903.386
118
OlneyJ. W.ZorumskiC. F.StewartG. R.PriceM. T.WangG. J.LabruyereJ. (1990). Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson’s and Huntington’s diseases.Exp. Neurol.108269–272. 10.1016/0014-4886(90)90134-e
119
PalS.HartnettK. A.NerbonneJ. M.LevitanE. S.AizenmanE. (2003). Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels.J Neurosci234798–4802. 10.1523/jneurosci.23-12-04798.2003
120
PalS.HeK.AizenmanE. (2004). Nitrosative stress and potassium channel-mediated neuronal apoptosis: is zinc the link?Pflugers Arch.448296–303. 10.1007/s00424-004-1256-7
121
PalS. K.TakimotoK.AizenmanE.LevitanE. S. (2006). Apoptotic surface delivery of K+ channels.Cell Death Differ.13661–667. 10.1038/sj.cdd.4401792
122
PaolettiP.AscherP. (1994). Mechanosensitivity of NMDA receptors in cultured mouse central neurons.Neuron13645–655. 10.1016/0896-6273(94)90032-9
123
PetrG. T.SunY.FrederickN. M.ZhouY.DhamneS. C.HameedM. Q.et al (2015). Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes.J. Neurosci.355187–5201. 10.1523/jneurosci.4255-14.2015
124
PinesG.DanboltN. C.BjorasM.ZhangY.BendahanA.EideL.et al (1992). Cloning and expression of a rat brain L-glutamate transporter.Nature360464–467.
125
PrabhuS. D.SalamaG. (1990). Reactive disulfide compounds induce Ca2+ release from cardiac sarcoplasmic reticulum.Arch. Biochem. Biophys.282275–283. 10.1016/0003-9861(90)90117-h
126
RedmanP. T.HartnettK. A.ArasM. A.LevitanE. S.AizenmanE. (2009a). Regulation of apoptotic potassium currents by coordinated zinc-dependent signalling.J. Physiol.5874393–4404. 10.1113/jphysiol.2009.176321
127
RedmanP. T.HeK.HartnettK. A.JeffersonB. S.HuL.RosenbergP. A.et al (2007). Apoptotic surge of potassium currents is mediated by p38 phosphorylation of Kv2.1.Proc. Natl. Acad. Sci. U.S.A.1043568–3573. 10.1073/pnas.0610159104
128
ReynoldsI. J.HastingsT. G. (1995). Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation.J. Neurosci.153318–3327. 10.1523/jneurosci.15-05-03318.1995
129
RedmanP. T.KnochM. E.AizenmanE. (2009b). “A zinc-potasium continuum in neuronal apoptosis,” in Brain hypoxia and Ischemia, edsHaddadG. G.YuS. P. (New York, NY: Humana Press), 97–115. 10.1007/978-1-60327-579-8_6
130
ReynoldsI. J.RushE. A.AizenmanE. (1990). Reduction of NMDA receptors with dithiothreitol increases [3H]-MK-801 binding and NMDA-induced Ca2+ fluxes.Br. J. Pharmacol.101178–182. 10.1111/j.1476-5381.1990.tb12109.x
131
RimmeleT. S.RosenbergP. A. (2016). GLT-1: the elusive presynaptic glutamate transporter.Neurochem. Int.9819–28. 10.1016/j.neuint.2016.04.010
132
RosenbergP. A. (1988). Catecholamine toxicity in cerebral cortex in dissociated cell culture.J. Neurosci.82887–2894. 10.1523/jneurosci.08-08-02887.1988
133
RosenbergP. A.AizenmanE. (1989). Hundred-fold increase in neuronal vulnerability to glutamate toxicity in astrocyte-poor cultures of rat cerebral cortex.Neurosci. Lett.103162–168. 10.1016/0304-3940(89)90569-7
134
RosenbergP. A.AminS.LeitnerM. (1992). Glutamate uptake disguises neurotoxic potency of glutamate agonists in cerebral cortex in dissociated cell culture.J. Neurosci.1256–61. 10.1523/jneurosci.12-01-00056.1992
135
RosenbergP. A.LoringR.XieY.ZaleskasV.AizenmanE. (1991). 2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin.Proc. Natl. Acad. Sci. U.S.A.884865–4869. 10.1073/pnas.88.11.4865
136
SanchezR. M.WangC.GardnerG.OrlandoL.TauckD. L.RosenbergP. A.et al (2000). Novel role for the NMDA receptor redox modulatory site in the pathophysiology of seizures.J. Neurosci.202409–2417. 10.1523/jneurosci.20-06-02409.2000
137
ScanlonJ. M.AizenmanE.ReynoldsI. J. (1997). Effects of pyrroloquinoline quinone on glutamate-induced production of reactive oxygen species in neurons.Eur. J. Pharmacol.32667–74. 10.1016/s0014-2999(97)00137-4
138
SchulienA. J.YehC. H.OrangeB. N.PavO. J.HopkinsM. P.MoutalA.et al (2020). Targeted-disruption of Kv2.1-VAPA association provides neuroprotection against ischemic stroke in mice by declustering Kv2.1 channels.Sci. Adv.6:eaaz8110. 10.1126/sciadv.aaz8110
139
SensiS. L.CanzonieroL. M.YuS. P.YingH. S.KohJ. Y.KerchnerG. A.et al (1997). Measurement of intracellular free zinc in living cortical neurons: routes of entry.J. Neurosci.179554–9564. 10.1523/jneurosci.17-24-09554.1997
140
SensiS. L.PaolettiP.KohJ. Y.AizenmanE.BushA. I.HershfinkelM. (2011). The neurophysiology and pathology of brain zinc.J. Neurosci.3116076–16085. 10.1523/jneurosci.3454-11.2011
141
SensiS. L.Ton-ThatD.SullivanP. G.JonasE. A.GeeK. R.KaczmarekL. K.et al (2003). Modulation of mitochondrial function by endogenous Zn2+ pools.Proc. Natl. Acad. Sci. U.S.A.1006157–6162. 10.1073/pnas.1031598100
142
SensiS. L.YinH. Z.CarriedoS. G.RaoS. S.WeissJ. H. (1999a). Preferential Zn2+ influx through Ca2+-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production.Proc. Natl. Acad. Sci. U.S.A.962414–2419. 10.1073/pnas.96.5.2414
143
SensiS. L.YinH. Z.WeissJ. H. (1999b). Glutamate triggers preferential Zn2+ flux through Ca2+ permeable AMPA channels and consequent ROS production.Neuroreport101723–1727. 10.1097/00001756-199906030-00018
144
SensiS. L.YinH. Z.WeissJ. H. (2000). AMPA/kainate receptor-triggered Zn2+ entry into cortical neurons induces mitochondrial Zn2+ uptake and persistent mitochondrial dysfunction.Eur. J. Neurosci.123813–3818. 10.1046/j.1460-9568.2000.00277.x
145
ShahN. H.AizenmanE. (2014). Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.Transl. Stroke Res.538–58. 10.1007/s12975-013-0297-7
146
SharmaA.KazimS. F.LarsonC. S.RamakrishnanA.GrayJ. D.McEwenB. S.et al (2019). Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer’s molecular signatures.Proc. Natl. Acad. Sci. U.S.A.11621800–21811. 10.1073/pnas.1903566116
147
SinorJ. D.BoeckmanF. A.AizenmanE. (1997). Intrinsic redox properties of N-methyl-D-aspartate receptor can determine the developmental expression of excitotoxicity in rat cortical neurons in vitro.Brain Res.747297–303. 10.1016/s0006-8993(96)01237-1
148
SteulletP.CabungcalJ. H.MoninA.DwirD.O’DonnellP.CuenodM.et al (2016). Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology?Schizophr. Res.17641–51. 10.1016/j.schres.2014.06.021
149
StorckT.SchulteS.HofmannK.StoffelW. (1992). Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain.Proc. Natl. Acad. Sci. U.S.A.8910955–10959. 10.1073/pnas.89.22.10955
150
SullivanJ. M.TraynelisS. F.ChenH. S.EscobarW.HeinemannS. F.LiptonS. A. (1994). Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor.Neuron13929–936. 10.1016/0896-6273(94)90258-5
151
TangL. H.AizenmanE. (1993a). Allosteric modulation of the NMDA receptor by dihydrolipoic and lipoic acid in rat cortical neurons in vitro.Neuron11857–863. 10.1016/0896-6273(93)90115-8
152
TangL. H.AizenmanE. (1993b). Long-lasting modification of the N-methyl-D-aspartate receptor channel by a voltage-dependent sulfhydryl redox process.Mol. Pharmacol.44473–478.
153
TangL. H.AizenmanE. (1993c). The modulation of N-methyl-D-aspartate receptors by redox and alkylating reagents in rat cortical neurones in vitro.J. Physiol.465303–323. 10.1113/jphysiol.1993.sp019678
154
TraynelisS. F.WollmuthL. P.McBainC. J.MennitiF. S.VanceK. M.OgdenK. K.et al (2010). Glutamate receptor ion channels: structure, regulation, and function.Pharmacol. Rev.62405–496.
155
Vander JagtT. A.ConnorJ. A.WeissJ. H.ShuttleworthC. W. (2009). Intracellular Zn2+ increases contribute to the progression of excitotoxic Ca2+ increases in apical dendrites of CA1 pyramidal neurons.Neuroscience159104–114. 10.1016/j.neuroscience.2008.11.052
156
VasakM.MeloniG. (2017). Mammalian metallothionein-3: new functional and structural insights.Int. J. Mol. Sci.18:1117. 10.3390/ijms18061117
157
WatkinsJ. C.JaneD. E. (2006). The glutamate story.Br. J. Pharmacol.147(Suppl. 1), S100–S108.
158
WhitingP.EschF.ShimasakiS.LindstromJ. (1987). Neuronal nicotinic acetylcholine receptor beta-subunit is coded for by the cDNA clone alpha 4.FEBS Lett.219459–463. 10.1016/0014-5793(87)80272-7
159
YehC. Y.BulasA. M.MoutalA.SalomanJ. L.HartnettK. A.AndersonC. T.et al (2017). Targeting a potassium channel/syntaxin interaction ameliorates cell death in ischemic stroke.J. Neurosci.375648–5658. 10.1523/jneurosci.3811-16.2017
160
YehC. Y.YeZ.MoutalA.GaurS.HentonA. M.KouvarosS.et al (2019). Defining the Kv2.1-syntaxin molecular interaction identifies a first-in-class small molecule neuroprotectant.Proc. Natl. Acad. Sci. U.S.A.11615696–15705. 10.1073/pnas.1903401116
161
YokoyamaM.KohJ.ChoiD. W. (1986). Brief exposure to zinc is toxic to cortical neurons.Neurosci. Lett.71351–355. 10.1016/0304-3940(86)90646-4
162
YuS. P.YehC. H.SensiS. L.GwagB. J.CanzonieroL. M.FarhangraziZ. S.et al (1997). Mediation of neuronal apoptosis by enhancement of outward potassium current.Science278114–117. 10.1126/science.278.5335.114
163
ZhangY.WangH.LiJ.DongL.XuP.ChenW.et al (2006). Intracellular zinc release and ERK phosphorylation are required upstream of 12-lipoxygenase activation in peroxynitrite toxicity to mature rat oligodendrocytes.J. Biol. Chem.2819460–9470. 10.1074/jbc.m510650200
164
ZhangY.WangH.LiJ.JimenezD. A.LevitanE. S.AizenmanE.et al (2004). Peroxynitrite-induced neuronal apoptosis is mediated by intracellular zinc release and 12-lipoxygenase activation.J. Neurosci.2410616–10627. 10.1523/jneurosci.2469-04.2004
165
ZottB.SimonM. M.HongW.UngerF.Chen-EngererH. J.FroschM. P.et al (2019). A vicious cycle of beta amyloid-dependent neuronal hyperactivation.Science365559–565. 10.1126/science.aay0198
Summary
Keywords
excitotoxicity, redox, NMDA receptor, catecholamine, zinc, potassium channel
Citation
Aizenman E, Loring RH, Reynolds IJ and Rosenberg PA (2020) The Redox Biology of Excitotoxic Processes: The NMDA Receptor, TOPA Quinone, and the Oxidative Liberation of Intracellular Zinc. Front. Neurosci. 14:778. doi: 10.3389/fnins.2020.00778
Received
16 May 2020
Accepted
02 July 2020
Published
24 July 2020
Volume
14 - 2020
Edited by
John Weiss, University of California, Irvine, United States
Reviewed by
Raymond A. Swanson, University of California, San Francisco, United States; David Lynch, University of Pennsylvania, United States
Updates
Copyright
© 2020 Aizenman, Loring, Reynolds and Rosenberg.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Elias Aizenman, redox@pitt.edu
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.